Abstract
Mutations in the actively expressed, maternal allele of the imprinted KCNK9 gene cause Birk-Barel intellectual disability syndrome (BBIDS). Using a BBIDS mouse model, we identify here a partial rescue of the BBIDS-like behavioral and neuronal phenotypes mediated via residual expression from the paternal Kcnk9 (Kcnk9pat) allele. We further demonstrate that the second-generation HDAC inhibitor CI-994 induces enhanced expression from the paternally silenced Kcnk9 allele and leads to a full rescue of the behavioral phenotype suggesting CI-994 as a promising molecule for BBIDS therapy. Thus, these findings suggest a potential approach to improve cognitive dysfunction in a mouse model of an imprinting disorder.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Behavior, Animal
-
Benzamides
-
Brain / metabolism
-
Craniofacial Abnormalities / drug therapy
-
Craniofacial Abnormalities / genetics*
-
Craniofacial Abnormalities / metabolism*
-
Disease Models, Animal
-
Female
-
Gene Knockdown Techniques
-
Genomic Imprinting
-
Histone Deacetylase Inhibitors / pharmacology
-
Histones / metabolism*
-
Humans
-
Intellectual Disability / drug therapy
-
Intellectual Disability / genetics*
-
Intellectual Disability / metabolism*
-
Locus Coeruleus / metabolism
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
Muscle Hypotonia / drug therapy
-
Muscle Hypotonia / genetics*
-
Muscle Hypotonia / metabolism*
-
Mutation
-
Phenotype
-
Phenylenediamines / pharmacology
-
Potassium Channels / deficiency
-
Potassium Channels / genetics*
-
Potassium Channels / metabolism
-
Up-Regulation / drug effects
Substances
-
Benzamides
-
Histone Deacetylase Inhibitors
-
Histones
-
Phenylenediamines
-
Potassium Channels
-
TASK3 protein, mouse
-
tacedinaline
Supplementary concepts
-
Birk-Barel Mental Retardation Dysmorphism Syndrome